Company profile
Innate Immunity Cancer Cure Biotech | LIfT BioSciences | United Kingdom
LIfT Biosciences is a pre-clinical stage biotech with The Worlds only Neutrophil based Cell Therapy Platform. The LIfT platform is allogeneic and can be used to produce different Immuno-Modulating Alpha Neutrophils (IMANs) for treating a range of different therapeutic indications, including solid tumours.
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
AA | Transaction MzQ1NTk2Njk4MmFkaXF6a2N4
Published 21 Feb 2025 10:47
CS01 | Transaction MzQ0MjE4ODY3NWFkaXF6a2N4
Published 06 Nov 2024 10:26
PSC07 | Transaction MzQ0MjA2OTI5NmFkaXF6a2N4
Published 05 Nov 2024 04:55
SH01 | Transaction MzQ0MjA2MzE2NGFkaXF6a2N4
Published 05 Nov 2024 03:49
AP01 | Transaction MzQzMjMzMjkwMWFkaXF6a2N4
Published 20 Aug 2024 08:39
AP01 | Transaction MzQzMjAwMDc1M2FkaXF6a2N4
Published 14 Aug 2024 15:08
TM01 | Transaction MzQzMjAwMTYzNGFkaXF6a2N4
Published 13 Aug 2024 15:22
AP01 | Transaction MzQzMjAwMTQ3OGFkaXF6a2N4
Published 13 Aug 2024 15:21
Company registered at Companies House
1 Sep 2024 to 31 Jul 2027
LIfT Biosciences Ltd (LIfT) is a disruptive biotech bringing to market a first-in-class immunomodulatory alpha neutrophil (IMAN) cell therapy designed to overcome the limitations of current immunotherapies in solid tumours. LIfT's ground-breaking IMANs not only directly kill tumour cells in an innate antigen-independent manner, but recruit and modulate re...
